Compare · ADN vs TMO
ADN vs TMO
Side-by-side comparison of Advent Technologies Holdings Inc. (ADN) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- ADN operates in Miscellaneous, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $222.97B, about 2727.3x ADN ($81.8M).
- Over the past year, ADN is down 71.7% and TMO is up 23.8% - TMO leads by 95.4 points.
- TMO has hit the wire 13 times in the past 4 weeks while ADN has been quiet.
- TMO has more recent analyst coverage (25 ratings vs 0 for ADN).
- Company
- Advent Technologies Holdings Inc.
- Thermo Fisher Scientific Inc
- Price
- -
- -
- Market cap
- $81.8M
- $222.97B
- 1M return
- -72.84%
- +1.54%
- 1Y return
- -71.65%
- +23.76%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 0
- 13
- Recent ratings
- 0
- 25
Advent Technologies Holdings Inc.
Advent Technologies Holdings, Inc., an advanced materials and technology development company, operates in the fuel cell and hydrogen technology markets. It develops, manufactures, and assembles the critical components that determine the performance of hydrogen fuel cells and other energy systems. The company offers HT-PEM (high-temperature proton exchange membrane) fuel cells, HT-PEM based membrane electrode assemblies, flow battery membranes, organic photovoltaics, and ultracells. It serves stationary power, portable power, automotive, aviation, energy storage, and sensor markets. The company was founded in 2006 and is headquartered in Boston, Massachusetts.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest ADN
- SEC Form 25-NSE filed by Advent Technologies Holdings Inc.
- SEC Form 25-NSE filed by Advent Technologies Holdings Inc.
- Advent Technologies Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits
- SEC Form 10-Q filed by Advent Technologies Holdings Inc.
- SEC Form NT 10-Q filed by Advent Technologies Holdings Inc.
- Advent Technologies Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement
- SEC Form 8-K filed by Advent Technologies Holdings Inc.
- Advent Technologies Powers the Future of Flight with Next-Generation Fuel Cell Technology
- Advent Technologies Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Advent Technologies Commissions Arxicon as Master Planner for RHyno Project
Latest TMO
- CLSA initiated coverage on Thermo Fisher with a new price target
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)
- SVP and General Counsel Shropshire Thomas B Jr. covered exercise/tax liability with 49 shares, decreasing direct ownership by 0.81% to 6,008 units (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. covered exercise/tax liability with 394 shares, decreasing direct ownership by 3% to 14,391 units (SEC Form 4)
- Sr. Vice President & CFO Meyer James covered exercise/tax liability with 270 shares, decreasing direct ownership by 5% to 5,560 units (SEC Form 4)
- Chairman & CEO Casper Marc N covered exercise/tax liability with 1,257 shares, decreasing direct ownership by 1% to 122,669 units (SEC Form 4)
- VP & Chief Accounting Officer Holmes Joseph R. covered exercise/tax liability with 50 shares, decreasing direct ownership by 2% to 2,916 units (SEC Form 4)
- President & COO Pettiti Gianluca covered exercise/tax liability with 1,035 shares, sold $2,539,233 worth of shares (4,133 units at $614.38) as part of a pre-agreed trading plan and exercised 3,733 shares at a strike of $309.63, decreasing direct ownership by 6% to 23,216 units (SEC Form 4)
- Thermo Fisher Scientific to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026
- Chairman & CEO Casper Marc N exercised 275 shares at a strike of $309.63 and sold $172,439 worth of shares (275 units at $627.05) as part of a pre-agreed trading plan (SEC Form 4)